Overview
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors. It activates three key metabolic hormone receptors simultaneously, producing synergistic effects on appetite suppression, energy expenditure, and glucose metabolism.
Key Characteristics:
– Extended half-life of approximately 6 days
– Enables convenient once-weekly subcutaneous dosing
– Studied for substantial weight loss and metabolic improvement in obesity and type 2 diabetes
—
Dosing & Reconstitution
Reconstitution Instructions
1. Draw 2.0 mL bacteriostatic water with a sterile syringe
2. Inject slowly down vial wall; avoid foaming
3. Gently swirl/roll until dissolved (do not shake vigorously)
4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light
Resulting Concentration: 2.5 mg/mL
Standard Gradual Titration Schedule
| Week(s) | Weekly Dose | Units (per injection) | Volume (mL) |
|---|---|---|---|
| 1–4 | 2,000 mcg (2 mg) | 80 units | 0.80 mL |
| 5–8 | 4,000 mcg (4 mg) | 160 units | 1.60 mL |
| 9–12 | 8,000 mcg (8 mg) | 320 units | 3.20 mL |
| 13+ | 12,000 mcg (12 mg) | 480 units | 4.80 mL |
Use multiple vials or split injections across different sites
Dosing Protocol Details
– Start: 2 mg once weekly for first 4 weeks to establish tolerability
– Escalation: Increase to 4 mg weekly (weeks 5–8), then 8 mg weekly (weeks 9–12)
– Maintenance: 12 mg weekly (week 13 onward) for maximum efficacy; 8 mg is an alternative maintenance dose
– Frequency: Once per week subcutaneously; consistent day/time recommended
– Cycle Length: Minimum 12 weeks for titration; clinical trials extended to 48 weeks
– Injection Measurement: At 2.5 mg/mL, 1 unit = 0.01 mL ≈ 25 mcg on U-100 insulin syringe
—
Storage Instructions
Lyophilized Vials:
– Store at −20 °C (−4 °F) or colder for long-term preservation
– Protect from moisture and light
Reconstituted Solution:
– Refrigerate at 2–8 °C (35.6–46.4 °F) immediately after mixing
– Use within 2–4 weeks for maximum potency
– Avoid repeated freeze-thaw cycles
– Never expose to heat or direct sunlight
—
Supplies Needed (12-48 Week Protocol)
Peptide Vials (5 mg each):
– 12 weeks: ~13 vials
– 24 weeks: ~40 vials
– 48 weeks: ~115 vials
Insulin Syringes (U-100, 1 mL):
– 12 weeks: 12 syringes
– 24 weeks: 24 syringes
– 48 weeks: 48 syringes
Bacteriostatic Water (10 mL bottles):
– 12 weeks: 3 bottles
– 24 weeks: 8 bottles
– 48 weeks: 23 bottles
Alcohol Swabs:
– 12 weeks: 24 swabs (1 × 100-count box)
– 24 weeks: 48 swabs (1 × 100-count box)
– 48 weeks: 96 swabs (1 × 100-count box)
—
How It Works
The GLP-1 component reduces appetite and slows gastric emptying. GIP enhances insulin secretion and supports fat metabolism. Glucagon receptor activation increases energy expenditure and promotes fat oxidation. This triple mechanism produces superior outcomes versus single or dual agonists.
Clinical Trial Results:
– Participants receiving 12 mg weekly lost an average of 24% of body weight over 48 weeks
– In adults with type 2 diabetes, retatrutide achieved approximately 17% weight loss at 36 weeks with HbA1c reductions of approximately 2.0%
– Meta-analysis of three trials (878 participants) confirmed significantly greater weight reduction than placebo with no significant increase in overall adverse events
—
Potential Benefits
– Substantial weight loss: up to 24% reduction in body weight at 48 weeks with 12 mg weekly dosing
– Significant HbA1c reductions (approximately 2.0%) in adults with type 2 diabetes
– Improvements in lipid profiles, blood pressure, and cardiovascular risk markers
– Once-weekly subcutaneous administration improves adherence compared to daily regimens
—
Side Effects & Considerations
Common Adverse Effects:
– Gastrointestinal effects (nausea, diarrhea, vomiting, constipation) are most common; typically mild-to-moderate and diminish over time
– Starting at 2 mg weekly (versus 4 mg) significantly reduces initial GI adverse events
– Mild injection site reactions (redness, swelling, discomfort) may occur
– Overall safety profile: no significant increase in overall adverse events compared to placebo
—
Injection Technique
Pre-Injection Preparation
– Wash hands thoroughly with soap and water
– Clean vial stopper with alcohol swab and allow to air dry
– Select injection site (abdomen, thigh, or upper arm) and clean with fresh alcohol swab; allow to dry completely
– Draw prescribed dose carefully; check for air bubbles and expel if present
Injection Procedure
– Pinch a skinfold of approximately 1 inch between thumb and forefinger
– Insert needle at a 90-degree angle (45-degree if subcutaneous fat layer is thin) into pinched skin
– Do not aspirate for subcutaneous injections
– Inject slowly and steadily; depress plunger completely
– Withdraw needle straight out and apply gentle pressure with clean gauze if needed
Post-Injection Care
– Dispose of used syringe immediately in a puncture-proof sharps container; never recap needles
– Return reconstituted vial to refrigerator promptly
– Rotate injection sites weekly (at least 1 inch apart) to prevent lipohypertrophy
– Monitor for excessive redness, swelling, or signs of infection at injection site
—
Lifestyle Optimization
– Nutrition: Adopt balanced, protein-forward diet (1.0–1.2 g/kg body weight) to preserve lean mass during weight loss
– Hydration: Maintain adequate fluid intake, especially during dose titration
– Physical Activity: Combine resistance training (2–3×/week) with moderate aerobic exercise
– Sleep & Stress: Prioritize 7–9 hours of quality sleep and implement stress management techniques
– Meal Timing: Some individuals find smaller, more frequent meals help manage GI side effects during initial titration
—
Important Notes
– Weekly consistency: Choose a specific day/time and maintain throughout protocol
– Gradual titration is essential; starting at 2 mg weekly significantly reduces initial GI side effects
– Use new sterile insulin syringes for each injection
– Monitor for gastrointestinal side effects; if severe, extend time at current dose before escalating
– For doses exceeding 1.0 mL, split into multiple injections at different sites or use multiple vials
—
Disclaimer
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational compound. Consult qualified healthcare professionals before considering any peptide protocol. This information is for research and educational purposes only.